期刊
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
卷 38, 期 3, 页码 411-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2018.04.005
关键词
KIT mutations; KIT D816V; Cutaneous mastocytosis; Systemic mastocytosis; Imatinib; Midostaurin; Avapritinib
Mastocytosis is a World Health Organization-defined clonal mast cell disorder characterized by significant clinicopathologic heterogeneity. Despite this diversity, a mutation of the KIT gene, most commonly D816V, is found in almost all cases and believed to be a driver lesion. Peripheral blood allele-specific oligonucleotide polymerase chain reaction can reliably detect KIT D816V and is used for the initial screening of adults with suspected systemic mastocytosis. The discovery of KIT mutations as central to the pathobiology of mastocytosis has prompted development of KIT-targeted agents, including imatinib and midostaurin (approved medications for patients with advanced systemic mastocytosis), and drugs in development, such as KIT D816V-specific inhibitor avapritinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据